At a glance
ClinicalIndex Comparison Record- ✓Advanced lung cancer or other solid tumor where biopsy is obtainable
- ✓Life expectancy greater than 12 weeks
- ✓Child-Pugh-Turcotte score less than 7
- ✓Adequate cardiac, pulmonary, hepatic, and renal function
- ✕Prior gene therapy
- ✕Tumor size greater than 25 cm
- ✕Severe viral infection (HBV, HCV, HIV)
- ✕Known HIV positive
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TCR-T Cells Targeting Cancer Cells for Immunotherapy of Lung Cancer and Other Solid Tumors: Phase I Clinical Trial
In Brief
A Phase 1 clinical trial evaluating TCR-T cells for Nonsmall Cell Lung Cancer and Solid Tumor, Adult. Currently recruiting, targeting 30 participants across 1 site.
Detailed Summary
Tumor organoids and TILs (and/or peripheral T cells) cultures will be established from fresh tissure of lung cancer and other solid tumors. Coculture will be utilized to screen tumor-responsive T cells which are further selected for monoclonal expansion and TCR cloning for engineered reconstitution of TCR-T cells. After verification by multiple in vitro and in vivo studies, a large number of TCR-T cells will be introduced back into the patients via vein, artery or fine needle punctured to the tumor, or combinations. In this phase I study, the safety, tolerance and preliminary efficacy of the TCR-T cell immunotherapy on human will firstly be assessed.
Study Details
Timeline
Interventions
Engineering TCR-T cells targeting lung tumor and other solid tumor will be transfused back the patients.